[L-dopa treatment of parkinsonism].
D000284:Administration, Oral; D000368:Aged; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009127:Muscle Rigidity / Q000188:drug therapy; D010292:Paresthesia / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D014202:Tremor / Q000188:drug therapy; D014555:Urination Disorders / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D004295:Dihydroxyphenylalanine
Obserwacje nad zastosowaniem L-dopa w leczeniu choroby parkinsona.